Date: 2014-12-15
Type of information: Fundraising
Company: Vect-Horus (France)
Investors: BpiFrance (France)
Amount: € 1.5 million
Funding type: fundraising
Planned used: The public-private research collaboration developed with the CNRS, Aix -Marseille University (AMU), the CEA and INSERM has allowed Vect-Horus to develop a portfolio of four international patent families, some already issued in Europe and the United States.
« This new fundraising, backed by a repayable advance from BPI allows Vect-Horus to fund in 2015 two of its major projects: the
regulatory preclinical development of its first vectorized neuroprotective therapeutic agent, but also to move towards an original proof of concept with a program in oncology » said Alexandre Tokay, chairman of the company. The first vectorized product of the company will enter regulatory preclinical development in January 2015.
Others: * On December 15, 2014, Vect-Horus, a biotechnology company that designs and develops peptide vectors that facilitate the delivery of drugs or imaging agents, notably in the brain, announced having raised € 1.5 million, from its historical shareholders, mostly professionals in the finance industry. In total, Vect-Horus raised in 9 years more than € 11 million, of which € 5 million in grants and research tax credit.
Therapeutic area: Technology - Services - Cardiovascular diseases - Cerebrovascular diseases
